New combo aims to shield heart while fighting tumors

NCT ID NCT06815575

Recruiting now Disease control Sponsor: Racura Oncology Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's side effects. About 53 participants will take part across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS SOLID TUMOURS

Contacts and locations

Locations

Asan Medical Centre
NOT_YET_RECRUITING

Seoul, South Korea
Cancer Care Foundation
RECRUITING

Miranda, New South Wales, 2228, Australia
Ewha Womans University MokDong Hospital
NOT_YET_RECRUITING

Seoul, South Korea
Gosford Hospital
RECRUITING

Gosford, New South Wales, 2250, Australia
Prince of Wales Hospital
RECRUITING

Shatin, Hong Kong
Queen Mary Hospital
RECRUITING

Hong Kong, 999077, Hong Kong
Samsung Medical Centre
NOT_YET_RECRUITING

Seoul, South Korea
Severance Hospital, Yonsei University, Health System
NOT_YET_RECRUITING

Seoul, South Korea
Wyong Hospital
RECRUITING

Wyong, New South Wales, 2259, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.